Tabula Rasa HealthCare, Inc. operates as a healthcare technology company in the United States. The company operates in two segments, CareVention HealthCare and MedWise HealthCare. It offers EireneRx, a cloud-based medication decision-support and e-prescribing platform to access patient medication-related information; and MedWise medication therapy management software, a cloud-based platform designed to aid in the identification and resolution of medication and health-related problems. The company also provides TruChart that offers electronic health records (EHR), care coordination, and financial management in one program allowing Programs of All-Inclusive Care for the Elderly (PACE) to track measurable outcomes in defined timeframes for the populations they serve; and PACElogic, which delivers sharable workflows comprising EHR, customer relationship management, claims adjudication, electronic data interchange, care management, coordination and planning, integration with community-based providers, and various federal and state that requires reporting. In addition, it offers DoseMeRx, a decision support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, drug concentrations, and genotypes to guide dose optimization; and PrescribeWellness, a PrescribeWellness, a patient engagement center platform. Further, the company provides clinical pharmacist collaboration, prescription fulfillment and adherence packaging, and pharmacy benefit management services, as well as health plan management services, including risk adjustment and third party administrator services. As of December 31, 2021, it served approximately 150 healthcare organizations; and 350 health plans and approximately 18,000 retail pharmacies. The company provides cloud-based software applications to assist prescribers and pharmacists. Tabula Rasa HealthCare, Inc. was founded in 2009 and is headquartered in Moorestown, New Jersey.
According to Tabula Rasa HealthCare, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -2.11. At the end of 2021 the company had a P/B ratio of 6.27.
Year | P/B ratio |
---|---|
2022 | -2.11 |
2021 | 6.27 |
2020 | 5.55 |
2019 | 5.41 |
2018 | 8.76 |
2017 | 3.83 |
2016 | 2.00 |
2015 | -4.64 |
2014 | -7.33 |
2013 | -9.15 |